Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | Andrea Heslin Smiley has been a director since December 2020. ... Ms. Smiley currently serves as President and Chief Executive Officer of VMS BioMarketing ... We believe that Ms. Smiley’s more than 25 years of commercialization and management experience in the biopharmaceutical industry in both public and private companies qualify her for service as a director of our Company. |
| 2022-04-08 | Andrea Heslin Smiley(2)(3) 54 Director (2) Member of the Audit Committee. (3) Member of the Governance and Nominating Committee. 2021 Director Compensation: Fees Earned or Paid in cash ($) 63,571, Restricted Stock Unit Awards ($) 44,915, Option Awards ($) 42,319, Total ($) 150,805. |
| 2023-04-17 | Andrea Heslin Smiley has been a director since December 2020. Ms. Smiley currently serves as President and Chief Executive Officer of VMS BioMarketing, a provider of clinical educator solutions, which she joined in 2008 as Vice President, Strategic Marketing. Prior to joining VMS BioMarketing, Ms. Smiley held several executive positions running therapeutic business units at Eli Lilly and Company and has extensive commercialization expertise. She served as a member of the board of directors of Zyla Life Sciences, a life sciences company, from April 2018 to May 2020, when Zyla Life Sciences merged with Assertio Holdings, Inc., at which time she joined the board of directors of Assertio Holdings, Inc. Ms. Smiley also serves as a member of the board of directors of ATAI Life Sciences B.V., clinical-stage biopharmaceutical company, and as an advisor to Agent Capital, a venture capital firm. Ms. Smiley earned her B.A. in Economics from DePauw University. We believe that Ms. Smiley’s more than 25 years of commercialization and management experience in the biopharmaceutical industry in both public and private companies qualify her for service as a director of our Company. |
| 2024-04-15 | Andrea Heslin Smiley has been a director since December 2020. She served on the Compensation Committee and Nominating and Governance Committee during 2023. 2023 Director Compensation shows $65,561 fees earned or paid in cash and $65,000 restricted stock unit awards, totaling $130,561. |
Data sourced from SEC filings. Last updated: 2026-03-05